Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib

	Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
	Xu, X.1,2,3; Li, N.3; Fan, Y.2,3
刊名	JOURNAL OF THORACIC ONCOLOGY
	2022-09-01
卷号	17
关键词	ALK non-small cell lung cancer (NSCLC) leptomeningeal metastases (LM)
ISSN号	1556-0864
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	ELSEVIER SCIENCE INC
WOS记录号	WOS:000858678101221
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129779]
专题	中国科学院合肥物质科学研究院
作者单位	1.Zhejiang Chinese Med Univ, Hangzhou, Peoples R China 2.Chinese Acad Sci, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Xu, X.,Li, N.,Fan, Y.. Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib[J]. JOURNAL OF THORACIC ONCOLOGY,2022,17.
APA	Xu, X.,Li, N.,&Fan, Y..(2022).Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib.JOURNAL OF THORACIC ONCOLOGY,17.
MLA	Xu, X.,et al."Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib".JOURNAL OF THORACIC ONCOLOGY 17(2022).